Kramer Anders, Patti Giuseppe, Nielsen-Kudsk Jens Erik, Berti Sergio, Korsholm Kasper
Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus, Denmark.
Department of Translational Medicine, University of Eastern Piedmont, 13100 Vercelli, Italy.
J Clin Med. 2024 Jan 30;13(3):803. doi: 10.3390/jcm13030803.
Left atrial appendage occlusion (LAAO) is an established alternative to oral anticoagulation for stroke prevention in atrial fibrillation. Antithrombotic therapy is used in the post-procedural period to prevent device-related thrombosis (DRT). The risk of DRT is considered highest in the first 45-90 days after device implantation, based on animal studies of the device healing process. Clinically applied antithrombotic regimens vary greatly across studies, continents, and centers. This article gives an overview of the evidence behind current antithrombotic regimens, ongoing randomized trials, and future post-procedural management.
左心耳封堵术（LAAO）是心房颤动患者预防卒中的一种成熟的口服抗凝替代方法。术后使用抗栓治疗以预防器械相关血栓形成（DRT）。基于器械愈合过程的动物研究，DRT风险在器械植入后的最初45 - 90天被认为最高。临床应用的抗栓方案在不同研究、各大洲及各中心之间差异很大。本文概述了当前抗栓方案背后的证据、正在进行的随机试验以及未来的术后管理。
